Table 4.
Combinations of PARP inhibitors with anti-angiogenic agents for the treatment of recurrent ovarian cancer
| Trial name/identification | Phase | Treatment(s) | Disease setting | Sample size | Follow-up (median months) | Objective response rate (%) | Progression-free survival (median months) | Overall survival (median months) |
| Liu et al. 201442 | II | Olaparib+ cediranib vs olaparib |
High-grade serous or endometrioid platinum-sensitive recurrent ovarian cancer | 90 | 16.6 | 79.6% vs 47.8% (p=0.002) | 17.7 vs 9.0 (p=0.005) | Immature |
| Liu et al. 2019 (update)60 | II | Olaparib+ cediranib vs olaparib |
High-grade serous or endometrioid platinum-sensitive recurrent ovarian cancer | 90 | 46 | Not reported | 16.5 vs 8.2 months (p=0.007). | 44.2 vs 33.3 (p=0.11) |
| GY004 (Liu et al. 2019)43 | III | Olaparib+ cediranib vs. olaparib vs standard of care |
High-grade serous or endometrioid or BRCA-related platinum-sensitive recurrent ovarian cancer | 528 | 29.1 | 69.4% vs 52.4% vs 71.3% | 10.4 vs 8.2 vs 10.3 | No significant difference/no significant difference |
| AVANOVA 244 | II | Niraparib+ bevacizumab vs niraparib |
High-grade serous or endometrioid platinum-sensitive recurrent ovarian cancer | 97 | 16.9 | 62% vs 30% (p=0.003) | 11.9 vs 5.5 (p<0.0001) | Immature |
| CONCERTO45 | IIb | Olaparib+ cediranib |
BRCA wild-type recurrent platinum-resistant ovarian cancer | 60 | not reported | 15.3 | 5.1 | 13.2 |
| BAROCCO (Colombo et al. 2019)46 | II | Olaparib+ cediranib continuous/intermittent schedule vs weekly paclitaxel |
Platinum-resistant recurrent ovarian cancer | 123 | Not reported | Not reported | 5.7/3.8 vs 3.1 | Not reported |
| OCTOVA (Nicum et al. 2021)47 | II | Olaparib vs olaparib+ cediranib |
High grade platinum-resistant ovarian cancer | 139 | Not reported | Not reported | Not reported | Not reported |
BRCA, BReast CAncer gene; PARP, poly-ADP ribose polymerase.